KALVISTA PHARMACEUTICALS INC (KALV) Fundamental Analysis & Valuation

NASDAQ:KALV • US4834971032

18.44 USD
+1.14 (+6.59%)
At close: Mar 10, 2026
17.0165 USD
-1.42 (-7.72%)
After Hours: 3/10/2026, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This KALV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, KALV scores 2 out of 10 in our fundamental rating. KALV was compared to 519 industry peers in the Biotechnology industry. Both the profitability and financial health of KALV have multiple concerns. KALV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. KALV Profitability Analysis

1.1 Basic Checks

  • In the past year KALV has reported negative net income.
  • In the past year KALV has reported a negative cash flow from operations.
  • In the past 5 years KALV always reported negative net income.
  • In the past 5 years KALV always reported negative operating cash flow.
KALV Yearly Net Income VS EBIT VS OCF VS FCFKALV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • KALV has a Return On Assets of -37.26%. This is in the better half of the industry: KALV outperforms 60.31% of its industry peers.
  • KALV has a Return On Equity of -745.01%. This is in the lower half of the industry: KALV underperforms 78.61% of its industry peers.
Industry RankSector Rank
ROA -37.26%
ROE -745.01%
ROIC N/A
ROA(3y)-48.3%
ROA(5y)-38.68%
ROE(3y)-54.5%
ROE(5y)-43.24%
ROIC(3y)N/A
ROIC(5y)N/A
KALV Yearly ROA, ROE, ROICKALV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • KALV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KALV Yearly Profit, Operating, Gross MarginsKALV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. KALV Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for KALV has been increased compared to 1 year ago.
  • Compared to 5 years ago, KALV has more shares outstanding
  • Compared to 1 year ago, KALV has a worse debt to assets ratio.
KALV Yearly Shares OutstandingKALV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
KALV Yearly Total Debt VS Total AssetsKALV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • KALV has an Altman-Z score of -1.79. This is a bad value and indicates that KALV is not financially healthy and even has some risk of bankruptcy.
  • KALV has a Altman-Z score (-1.79) which is in line with its industry peers.
  • A Debt/Equity ratio of 15.81 is on the high side and indicates that KALV has dependencies on debt financing.
  • KALV's Debt to Equity ratio of 15.81 is on the low side compared to the rest of the industry. KALV is outperformed by 82.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 15.81
Debt/FCF N/A
Altman-Z -1.79
ROIC/WACCN/A
WACCN/A
KALV Yearly LT Debt VS Equity VS FCFKALV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • KALV has a Current Ratio of 7.22. This indicates that KALV is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 7.22, KALV is in the better half of the industry, outperforming 70.13% of the companies in the same industry.
  • A Quick Ratio of 7.21 indicates that KALV has no problem at all paying its short term obligations.
  • The Quick ratio of KALV (7.21) is better than 70.13% of its industry peers.
Industry RankSector Rank
Current Ratio 7.22
Quick Ratio 7.21
KALV Yearly Current Assets VS Current LiabilitesKALV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. KALV Growth Analysis

3.1 Past

  • KALV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.67%.
EPS 1Y (TTM)-4.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • KALV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.03% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.1%
EPS Next 2Y21.22%
EPS Next 3Y31.05%
EPS Next 5Y25.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KALV Yearly Revenue VS EstimatesKALV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
KALV Yearly EPS VS EstimatesKALV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. KALV Valuation Analysis

4.1 Price/Earnings Ratio

  • KALV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KALV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KALV Price Earnings VS Forward Price EarningsKALV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KALV Per share dataKALV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

  • KALV's earnings are expected to grow with 31.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.22%
EPS Next 3Y31.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KALV Dividend Analysis

5.1 Amount

  • No dividends for KALV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KALV Fundamentals: All Metrics, Ratios and Statistics

KALVISTA PHARMACEUTICALS INC

NASDAQ:KALV (3/10/2026, 8:00:03 PM)

After market: 17.0165 -1.42 (-7.72%)

18.44

+1.14 (+6.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-08
Earnings (Next)03-17
Inst Owners126.03%
Inst Owner Change9.56%
Ins Owners1.82%
Ins Owner Change12.27%
Market Cap932.14M
Revenue(TTM)N/A
Net Income(TTM)-126.64M
Analysts86.67
Price Target34.68 (88.07%)
Short Float %44.33%
Short Ratio20.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-44.72%
Min EPS beat(2)-102.71%
Max EPS beat(2)13.27%
EPS beat(4)2
Avg EPS beat(4)-45.86%
Min EPS beat(4)-106.51%
Max EPS beat(4)13.27%
EPS beat(8)4
Avg EPS beat(8)-27.38%
EPS beat(12)8
Avg EPS beat(12)-13.2%
EPS beat(16)12
Avg EPS beat(16)-7.27%
Revenue beat(2)1
Avg Revenue beat(2)-4.89%
Min Revenue beat(2)-95.99%
Max Revenue beat(2)86.21%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.66%
PT rev (3m)9.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.43%
EPS NY rev (1m)17.15%
EPS NY rev (3m)17.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 54.84
P/tB 54.84
EV/EBITDA N/A
EPS(TTM)-3.81
EYN/A
EPS(NY)-1.8
Fwd EYN/A
FCF(TTM)-4.01
FCFYN/A
OCF(TTM)-3.96
OCFYN/A
SpS0
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37.26%
ROE -745.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.3%
ROA(5y)-38.68%
ROE(3y)-54.5%
ROE(5y)-43.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 15.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 213.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.22
Quick Ratio 7.21
Altman-Z -1.79
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)129.01%
Cap/Depr(5y)89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.1%
EPS Next Y12.1%
EPS Next 2Y21.22%
EPS Next 3Y31.05%
EPS Next 5Y25.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.84%
EBIT Next 3Y-7.69%
EBIT Next 5YN/A
FCF growth 1Y-137.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-137.59%
OCF growth 3YN/A
OCF growth 5YN/A

KALVISTA PHARMACEUTICALS INC / KALV FAQ

Can you provide the ChartMill fundamental rating for KALVISTA PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 2 / 10 to KALV.


What is the valuation status for KALV stock?

ChartMill assigns a valuation rating of 1 / 10 to KALVISTA PHARMACEUTICALS INC (KALV). This can be considered as Overvalued.


How profitable is KALVISTA PHARMACEUTICALS INC (KALV) stock?

KALVISTA PHARMACEUTICALS INC (KALV) has a profitability rating of 1 / 10.


What is the financial health of KALVISTA PHARMACEUTICALS INC (KALV) stock?

The financial health rating of KALVISTA PHARMACEUTICALS INC (KALV) is 3 / 10.


What is the earnings growth outlook for KALVISTA PHARMACEUTICALS INC?

The Earnings per Share (EPS) of KALVISTA PHARMACEUTICALS INC (KALV) is expected to grow by 12.1% in the next year.